NCT04042324View on ClinicalTrials.gov

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions
End Stage Renal Disease
Interventions
DRUG

Triferic

Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.

DRUG

Heparin

Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

All Listed Sponsors
lead

Rockwell Medical Technologies, Inc.

INDUSTRY

NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients | Biotech Hunter | Biotech Hunter